Insight, China's Pharmaceutical Industry

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...

Company Drug PIC

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Fineline Cube Aug 5, 2026

Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...

Company PIC

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Fineline Cube Aug 5, 2026

Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...

Company Drug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...

Company PIC

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

Fineline Cube Aug 5, 2026

Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...

Company PIC

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Fineline Cube Aug 5, 2026

AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...

Company PIC

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Fineline Cube Aug 5, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026

In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...

Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026

CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...

Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...

Company Drug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Fineline Cube Aug 5, 2026

Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...

Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Fineline Cube Aug 4, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Fineline Cube Aug 4, 2026

On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Aug 4, 2026

Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...

Company PIC

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Fineline Cube Aug 4, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...

Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026

Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...

Company Medical Device

Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits

Fineline Cube Aug 4, 2026

Sansure Biotech Inc. (SHA: 688289) announced that five of its nucleic acid diagnostic kits have...

Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Fineline Cube Aug 4, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s TQB2102,...

Insight, China's Pharmaceutical Industry

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

You Missed

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer

Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i